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Abstract
Inflammatory bowel disease (IBD) is a chronic relapsing inflammatory disorder of the bowel. The
etiology remains unknown, but IBD is immune-driven and multiple factors including genetic,
environmental, and microbiological components play a role. Recombinase-activating gene-2-
deficient (Rag2−/−) mice infected with Helicobacter hepaticus (H. hepaticus) have been developed
as an animal model to imitate naturally occurring inflammatory events and associated key features
of chronic inflammatory responses in humans. In this study, we have combined mass
spectrometry-based metabolomics and peptidomics to analyze serum samples of Rag2−/− mice
infected with H. hepaticus. Metabolomics profiling revealed that H. hepaticus infection
dramatically changed numerous metabolite pathways, including tryptophan metabolism,
glycerophospholipids, methionine-homocysteine cycle, citrate cycle, fatty acid metabolism and
purine metabolism, with the majority of metabolites being down-regulated. In particular, there
were notable effects of gut microflora on the blood metabolites in infected animals. In addition,
the peptidomics approach identified a number of peptides, originating from proteins, including
fibrinogen, complement C4 and alpha-2-macroglobulin, with diverse biological functions with
potentially important implications for the progress of IBD. In summary, the strategy of integrating
a relevant animal model and sensitive mass spectrometry-based profiling may offer a new
perspective to explore biomarkers and provide mechanistic insights into IBD.
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1. Introduction
Inflammatory bowel disease (IBD) is a chronic relapsing inflammatory disorder of the
bowel, with more than a million patients in U.S. suffering from this debilitating disease1.
IBD significantly increases the risk of colorectal cancer in humans 2. Many factors
contribute to the occurrence and perpetuation of this disease and both genetic and
environmental factors may play an important role3,4. The etiology remains unclear, although
intestinal microbiota and host immunity are pivotal in the disease progression in the lower
bowel 5–8. Commensal enteric bacteria are important factors that drive the progression of
IBD 6; animal models have shown that intestinal bacterial flora are also important in the
development of this disease 9–11 and altered gut microflora in IBD patients are a common
component of the pathophysiology12–15.
Recombinase-activating gene-2-deficient (Rag2−/−) mice lack functional lymphocytes16 and
have been used as an animal model to investigate IBD17–19. Rag2−/− mice infected with
Helicobacter hepaticus (H. hepaticus) have been shown to emulate inflammatory events in
humans, including characteristic key features such as accumulation of macrophages and
neutrophils in the colon, generation of nitric oxide, up-regulation of inducible NO synthase
and increased expression tumor necrosis factor-alpha (TNF-alpha) 17–19.
Early detection, mechanistic insights, and development of therapeutic targets largely depend
on available biomarkers, and metabolomics is emerging as a powerful tool for characterizing
and developing biomarkers associated with human diseases, including IBD. Nuclear
magnetic resonance (NMR) and mass spectrometry (MS) are widely used to profile
metabolites in diverse biological samples, and several studies have been conducted in animal
models and IBD patients to analyze metabolites in urine, fecal extracts and biopsy samples,
with NMR being a major tool20–25. Recently, however, MS-based metabolomics profiling is
becoming attractive because of its high sensitivity, the ability to detect molecules with
diverse structures, a wide dynamic range, quantitative capability and the ease of interfacing
with other separation techniques such as gas and liquid chromatography.
In this study, we applied a liquid chromatography-mass spectrometry (LC-MS)
metabolomics approach to analyze global metabolite changes in Rag2−/− mice infected with
H. hepaticus for different time periods (10 week post-infection and 20 week post-infection).
This non-targeted metabolomics profiling revealed a notable effect of H. hepaticus infection
in Rag2−/− mice, with large numbers of metabolites being down-regulated. Our data also
clearly illustrated large effects of gut flora on blood metabolites during infection. In
addition, we have complemented our metabolomics analysis with peptidomics and identified
a number of serum peptides that originate from up-regulated proteins. These precursor
proteins, with diverse biological functions, may have important implications for the progress
of IBD.
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2. Experimental Section
Animals
Experiments were conducted in 129/SvEv Rag2−/− mice housed in the MIT Department of
Comparative Medicine in static microisolator cages and were approved by the Institutional
Animal Care and Use Committee. Each grouping was comprised of 10 mice unless
otherwise stated. Mice manipulation and histopathologic evaluation were conducted as
described previously26.
Helicobacter hepaticus
H. hepaticus (strain 3B1, ATCC 51449) was grown and the purity was confirmed as
described previously17. At age 6–8 weeks, mice were dosed with H. hepaticus by gavage
every other day for a total of 3 doses. Control mice were dosed with vehicle alone. H.
hepaticus infection was confirmed by examining cecum and colon with PCR using H.
hepaticus-specific primers. Serum and tissues were collected at 10 and 20 weeks post-
infection.
Metabolite extraction
Metabolites were isolated from serum using methanol. Internal standard stock solution
containing a synthetic peptide (10 FL) and cold methanol (80 FL) were added to 10 FL of
serum. After vortexting for 1 minute, the samples were incubated at 4 °C for 20 minutes and
then centrifuged for 10 minutes at 12,000 rpm. The supernatant was collected, dried in a
SpeedVac, and then resuspended in 30 FL of 98:2 water:acetonitrile for MS analysis.
Metabolomics profiling by LC-MS
LC-MS analyses were performed on a LC/MSD time-of-flight (TOF) mass spectrometer
from Agilent (Santa Clara, CA) with an electrospray ionization (ESI) source. The mass
spectrometer was interfaced with a 1290 Ultra Performance Liquid Chromatography system
from Agilent (Santa Clara, CA). The ESI-TOF was calibrated daily using the standard
tuning solution from the Agilent Technologies. During analyses, the instrument was
calibrated using two different reference masses with constant infusion. The typical mass
accuracy of ESI-TOF was less than 5 ppm. Metabolites were analyzed in both positive and
negative modes using a C18 T3 reverse phase column from Waters (Milford, MA). For
positive mode experiments, the mobile phases were water with 0.1% formic acid (A) or
acetonitrile with 0.1% formic acid (B). A linear gradient was run from 2% to 90% B over 60
minutes, at 200 FL/min. The ESI source parameters were: spray voltage, 3.5 kV; gas
temperature, 325 °C; drying gas, 12 L/min; nebulizer, 35 psig; fragmentor, 160 V. In
negative mode, the mobile phases were water with 1 mM ammonium fluoride (A) or
acetonitrile (B). Similarly, a linear gradient was run from 2% to 90% B over 45 minutes,
with a flow rate of 200 FL/min. The ESI source was set as follows: spray voltage, 3.0 kV;
gas temperature, 325 °C; drying gas, 11 L/min; nebulizer, 30 psig; fragmentor, 165 V.
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Data processing and analysis
Data acquired in Agilent. d format were converted to mzXML using MassHunter
Workstation software from Agilent (Santa Clara, CA). Data were filtered by intensity; only
signals with intensities larger than 1000 were considered. The converted data were
processed by both MassProfiler Professional (MPP) software (Agilent, Santa Clara, CA) and
XCMS (Scripps, La Jolla, CA) for peak picking, alignment, integration and extraction of the
peak intensities. To profile individual metabolite differences between uninfected and
infected groups, a 2-tailed Welch’s t-test was used (p < 0.05). The exact masses of
molecular features with significant changes were searched against the Human Metabolome
Database (HMDB) (http://www.hmdb.ca), METLIN (http://metlin.scripps.edu) and Kyoto
Encyclopedia of Genes and Genomes (KEGG) databases (http://www.genome.jp/kegg). The
matched exact masses were stored and used for the generation of MS/MS data to further
identify the metabolites.
Metabolite identification
MS/MS was generated on an Agilent Q-TOF 6510 mass spectrometer (Santa Clara, CA) to
further confirm the identity of the metabolites. The Q-TOF was calibrated daily using the
standard tuning solution from the Agilent Technologies. The instrument was calibrated
using two different reference masses with constant infusion during the analyses. The typical
mass accuracy was less than 5 ppm. Metabolites were extracted from 30 FL of pooled serum
samples for MS/MS experiments. The column and gradients were the same as those used for
metabolite profiling by ESI-TOF. The ESI source was set as follows: spray voltage, 3.5 kV;
gas temperature, 325 °C; drying gas, 10 L/min; nebulizer, 32 psig; fragmentor, 150 V. A
target list, which included previously determined exact masses according to the database
search results, was generated for fragmentation. The retention-time differences between
ESI-TOF and Q-TOF for each compound were corrected by manual alignment.
Statistical analysis
Data analysis was conducted with multivariate statistical methods. Principle component
analysis (PCA) was performed to examine intrinsic clusters and obvious outliers within the
observations. To identify potential outliers in samples, 95% confidence interval of all
samples was used as the threshold. In addition, heat maps were generated using a
hierarchical clustering algorithm to visualize the metabolite difference within the dataset.
All data handling and statistical analysis were performed using the statistical R package.
Identification of serum peptides
The charge states of peptides with significant changes were determined from the isotope
clusters. The exact masses, charge states and corresponding retention times were used to
make a target list for Q-TOF MS/MS experiments. The collision energies were dependent on
the size and charge of peptides, ranging from 13 to 25V. The resultant tandem mass spectra
were extracted and searched against the NCBInr database with Agilent Spectrum Mill
Software (Santa Clara, CA) to identify the sequences and potentially matched proteins.
Spectrum Mill MS/MS search parameters were set as follows: database, NCBInr.fasta;
species, Mus Musculus; protein pI, 3 to 10; modification, none; digestion, no enzyme;
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precursor mass tolerance, 20 ppm; product mass tolerance, 200 ppm; batch size, 25; search
mode, identity. Peptides with Scores > 10, Scored Peak Intensity Percent (%SPI) > 65 and
Fwd-Rev Score >2 were considered tentative identification27,28 and two peptide sequences
were further validated using authentic synthetic peptides.
3. Results
3.1 Method development and LC-MS chromatograms
Figure 1 shows the experimental workflow for the initial metabolite profiling. Briefly, ten
serum samples each from uninfected or infected Rag2−/− mice were extracted and analyzed
by ESI-TOF, over a range of 80–1000m/z, in both positive and negative polarities, using a
C18 reverse phase analytical column. Molecular features, i.e., all signals associated with a
given analyte, with intensities larger than 1000 were further processed and statistically
analyzed with MPP or XCMS software to profile metabolites with significant changes (1.5
fold change, p<0.05) between the uninfected and infected animals. The resultant peak list
with exact masses was searched against metabolite databases including HMDB and
METLIN, with a 10 ppm mass accuracy threshold. Next, the matched exact masses and
associated retention times were used to generate MS/MS spectra to confirm the metabolite
identities, followed by metabolic pathway or function analysis with the KEGG database.
Figure 2 shows typical LC-ESI-TOF total-ion chromatograms of serum metabolites
extracted from uninfected and infected animals, acquired under ESI positive mode. Several
dominant compounds can be noted by inspection. For example, the intense peak eluting at
11.87 min is tryptophan. The strong peaks at 40–45 min are attributed to lysophosphatidyl
cholines (Lyso-PC). The wide peaks between 30–35 min are largely residual serum proteins
after methanol extraction.
Several peaks with different intensities, marked by asterisks in the TIC, could be readily
observed between the uninfected and infected animal, while molecular feature extraction
revealed an additional large number of metabolites with significantly-changed
concentrations. The reproducibility of the LC-MS system, with less than 20-second
retention-time shifts from run to run, facilitated good alignments within the datasets (Figure
S1). From a typical positive LC-ESI-TOF chromatogram, more than 10,000 molecular
features could be extracted (Table 1), although a given metabolite could be represented by
several different molecular features. For example, it may have several isotope peaks and
nonspecific or unknown adduct ions. Moreover, much fewer metabolites were captured by
negative ESI-TOF (Table 1); some typical total ion chromatograms are shown in Figure S2.
An initial assessment of the effect of H. hepaticus infection in Rag2−/− mice revealed a
significant effect on the metabolite profiles (Table 1). Approximately 10% and 20% of the
total features were changed for 10 week and 20 week infection groups, respectively, with the
majority (~80%) being down-regulated.
3.2 Multivariate statistical analysis
We next used multivariate statistics to examine the intrinsic clusters within each group and
whether the uninfected and infected groups could be differentiated using metabolite profiles.
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PCA revealed excellent separations of the uninfected and infected animals under both
positive and negative modes, as illustrated in Figure 3 A and 3C. The hierarchical clustering
heat maps in Figure 3B and 3D show similar patterns within each group and confirm that the
majority of metabolites were down-regulated in infected animals. A good separation was
also observed for the 10-week samples, with one animal in the uninfected group identified as
an outlier using the 95% confidence interval as the threshold (Figure S3A and S3C). The
different pattern of that sample revealed by the hierarchical clustering heat map also
supports this identification (Figure S3B and S3D). Interestingly, the metabolite features of
infected animals are more homogeneous than those of uninfected animals, as illustrated by
closer clustering in Figure 3A, suggesting that cellular responses to H. hepaticus infections
are largely driving the biology in infected animals.
3.3 Identification of metabolites
Identifying the compounds that show significant differences between the uninfected and
infected mice is the most laborious and time-consuming aspect of non-targeted
metabolomics, involving database searches with exact masses followed by interpretation of
MS/MS product-ion spectra. Figure S4 illustrates the process for the identification of
metabolites with hippuric acid as an example, which decreased 3-fold in the 20-week
infected samples. Database searching, using the exact mass at m/z 180.0645, gave 3–5 hits
depending on the database. The product-ion spectrum arising from m/z 180.0645 at 15.1 min
included characteristic hippuric acid fragments at m/z 77.0391 and m/z 105.0331 (Figure
S4). Comparison of the retention time and fragmentation pattern with an authentic standard
further confirmed the identity.
Table 2 summarizes the selected metabolites with greater than 1.5 fold changes (increase or
decrease relative to uninfected) between the uninfected and infected mice. More-complete
lists of identified metabolites in the 10 week and 20 week groups are shown in Table S1 and
S2. We identified totally 27 and 50 significantly changed metabolites in the 10 week and 20
week post-infection groups, respectively. The variety of these structures, including lipids,
amino acid derivatives, peptides, fatty acids, and nucleoside conjugates, highlight the
capability and advantages of non-targeted mass spectrometry-based metabolomics profiling.
3.4 Effect of infection period on the metabolite profile
The infection period of H. hepaticus has a significant impact on the metabolite profile in
Rag2−/− mice, which is reflected not only by a doubling of the number of changed
metabolites in the 20 week groups (Table 1), but also by larger fold changes of specific
metabolites in these mice. Figure 4 illustrates the influence of infection period on the fold
changes of some metabolites. Typically, 20-week infected samples have equivalent or higher
fold changes for the same metabolite compared to 10 week infected mice. These metabolite
changes are accompanied by the progressive development of colonic inflammation,
hyperplasia, dysplasia and colon adenocarcinoma caused by H. hepaticus infection in this
animal model17,19,26. Specifically, inflammation, edema, epithelial defects, crypt atrophy,
hyperplasia and dysplasia were common histopathologic changes for both 10-week and 20-
week infected mice, with ileocecocolic junction and proximal colon being the most severely
damaged locations. However, progression of dysplasia to intramural carcinoma was
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observed in selected 20-week H. hepaticus infected mice, which was characterized by
invasion of neoplastic glands below the muscularis mucosae layer. Portal and lobular
hepatitis were clearly identified in the liver tissues of both 10-week and 20-week H.
hepaticus infected Rag2−/− mice26. In addition, a previous study also demonstrated that H.
hepaticus infection induced progressive hepatitis in SCID/NCr mice including Kupffer, Ito,
oval cell hyperplasia and multifocal to coalescing coagulative hepatocyte necrosis29.
3.5 Effects of gut microflora on the metabolites in Rag2−/− mice infected with H. hepaticus
A number of indole derivatives were down-regulated in H. hepaticus infected Rag2−/− mice,
as shown in Figure 5A. Among these indole-containing compounds, 3-indolepropionic acid
(IPA) is of particular interest since this metabolite can only be generated by certain types of
bacteria 30,31 The decreased amount of IPA suggests that the gut microflora were perturbed
by the H. hepaticus infection. The effect of intestinal flora is further indicated by the
changes of other gut microbe-regulated metabolites including hippuric acid and
phenylacetylglycine, as illustrated in Figure 5B. Likewise, an increased amount of daidzein
suggests down-regulated metabolic activity that also involves gut bacteria, as shown in
Figure 5C. Taken together, these results clearly implicate the involvement of gut microflora
on the metabolite profiles in H. hepaticus infected Rag2−/− mice.
3.6 Altered lipid metabolism and methionine-homocysteine cycle in Rag2−/− mice infected
by H. hepaticus
N-methyl-histamine, which was synthesized by histamine N-methyltransferase using S-
adenosylmethionine (SAM) as the methyl donor, increased approximately 3-fold in infected
mice, as shown in Figure 6,. Meanwhile, we detected decreased amounts of S-
adenosylhomocysteine (SAH), which is generated by SAM during methylation. Reduced
levels of SAH, a central intermediate of the methionine-homocysteine cycle, suggests that
other methylation pathways have been inhibited during infection. Previous work established
that phosphatidylethanolamine methyltransferase (PEMT) converts
phosphatidylethanolamine (PE) to phosphatidylcholine (PC) using SAM as a methyl donor
with SAH as a by-product and accounts for 20~40% of normal hepatic PC synthesis 32. As
shown in Table 2 and Table S1–2, a number of phospholipids were significantly down-
regulated in our model. Therefore, a link may exist between altered phospholipid
metabolism and the impaired methionine-homocysteine cycle in H. hepaticus infected
Rag2−/− mice as illustrated in Figure 6.
3.7 Altered energy metabolism and fatty acid pathways
Our metabolomics profiling has shown that intermediates and cofactors of the TCA cycle
change during inflammation. Decreased citric acid (−3.69 fold) and increased flavin adenine
dinucleotide (FAD) (+1.73 fold) support the down-regulation of energy metabolism in our
model. In accordance with this observation, a number of unsaturated fatty acids decreased
upon infection, which may be the consequence of increased fatty acid oxidation induced by
oxidative stress and upregulation of peroxisomes. The interplay between energy metabolism
and fatty acid pathways is illustrated in Figure 7.
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3.8 Increased endogenous peptides in Rag2−/− mice infected by H. hepaticus
Although H. hepaticus down-regulates the majority of metabolites in Rag2−/− mice, a small
fraction of molecular features nonetheless is elevated during infection. A striking
observation was that multiply-charged ions predominated among these species, suggesting
that they were peptides, and we extended our standard metabolomics approach to
peptidomics, i.e., targeted peptide sequencing to identify potential precursor proteins which
share and, consequently, may generate, these sequences by protease processing. We again
relied on the exact masses, tandem MS/MS spectra and database searching; an example is
shown in Figure S5. Some selected peptides that were identified, as well as corresponding
presumed precursor proteins, are listed in Table 3. The annotated MS/MS spectra with
matched ions and fragments are listed in Figure S6.
4. Discussion and conclusion
A large number of metabolites were significantly changed in Rag2−/− mice following
infection with H. hepaticus, an IBD animal model, with the majority being down-regulated
in infected animals. Database searching using exact masses coupled with tandem MS/MS
analysis identified a number of significantly changed metabolites. Pathway analysis revealed
that tryptophan metabolism was the major perturbed pathway, followed by phenylalanine
and linoleic acid metabolism (Figure S7). Also, we unambiguously demonstrated the
involvement of gut microflora on the blood metabolite profiles in these animals. Moreover,
we identified many elevated serum peptides, which arise from proteins with diverse
functions and important implications for the development and progression of IBD. These
peptides are undoubtedly generated by unknown proteases in the serum.
We have found that a number of gut microbiome-regulated serum metabolites changed
during infection, which could be the consequence of impaired gut microflora induced by
enteric H. hepaticus. An elegant study using germ-free and conventional mice has revealed
the large effects of gut microflora on mammalian blood metabolites31. Another study also
found that the metabolic rate in germ-free mice is lower than in their conventional
counterparts33, highlighting the important role of gut microflora on the metabolic activity of
the host. Notably, previous studies have demonstrated that helicobacter infections perturb
the gut microflora in mice34,35. Particularly, the colonization dynamics of Altered Schaedler
Flora is influenced by H. hepaticus and H. trogontum infection in Swiss Webster mice and
B6.129P2-IL10 tm1Cgn mice, respectively34,35.
Specifically, we identified several indole-containing metabolites that decreased severalfold
in infected mice. IPA appears to be a specific indicator of imbalanced gut bacteria since a
gut bacterial metabolic process is needed to synthesize this compound 30. A recent study
identified Clostridium sporogenes as the only species, among 24 representative intestinal
flora tested, to produce IPA31. Thus, lower amounts of IPA may indicate that Clostridium
sporogenes or species with similar functions have been suppressed. Hippuric acid is another
gut bacteria-regulated metabolite, which decreased approximately 3-fold in mice infected for
20 weeks. This observation is in good agreement with previous reports of reduced hippurate
synthesis in IBD patients36. An alteration in the intestinal microbiota has been proven
responsible for the reduced synthesis of hippuric acid, although the relevant gut flora have
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not been identified 36. Another example to support the role of gut bacteria on the blood
metabolite profile is the metabolism of daidezin, i.e., its conversion to equol by intestinal
bacteria 37. The increased levels of daidezin detected in this study suggest a reduced growth
or decreased enzymatic activity of metabolizing bacteria.
The large effects of gut microflora may also be reflected by down-regulated phospholipid
synthesis. We detected a number of decreased Lyso-PCs and Lyso-PEs in the serum of
infected animals. Although synthesis and regulation of lipids are complicated, phospholipids
in blood could be impacted by the changes of gut microflora. The gut microbiota modulates
lipid metabolism, and germ-free mice have lower PC species and other phospholipids in
blood than do conventionally raised animals 38. Thus, the decreased amounts of
phospholipids in this study may mirror another aspect of the influence of gut microflora on
biochemical reactions.
We also discovered that N-methyl-histamine increased 3-fold in our animal model, which is
in accordance with the previous report that IBD patients have higher N-methyl-histamine 39.
Histamine N-methyltransferase catalyzes the methylation of histamine, primarily released
from mast cells, in the presence of SAM 39. SAM serves as a methyl donor and is involved
in methionine-homocysteine cycle. SAH is generated after losing the methyl group from
SAM and is tightly regulated by this cycle. Formation of higher amounts of N-methyl-
histamine should induce higher levels of SAH. Contrary to our expectation, SAH dropped
approximately 2 fold in infected animals. This evidence may point to other regulated methyl
transfer pathways, which also use SAM as a methyl donor. The PC synthesis via PEMT is a
major user of the methyl group of SAM and regulates plasma homocysteine 32. Inhibited
synthesis of PC from PE via methylation may contribute to decreased SAH. Thus, reduced
synthesis of PC from PE could correlate with the methionine-homocysteine cycle and
account for the down-regulation of SAH due to lower availability of SAM as a methyl
donor. There is increasing appreciation of the possible association between lipid synthesis
and methylation in human nutrition and diseases40,41. Reduced synthesis of PC contributes
to an altered methionine-homocysteine cycle, although this does not rule out the possibility
that other methylation pathways are also regulated in infected mice. In addition, an induced
expression of SAH hydrolase or inhibited SAM synthetase may also lead to a lower level of
SAH 42.
We have shown that the TCA cycle is inhibited in infected mice, as supported by a
decreased intermediate and increased cofactor. Accumulating evidence has highlighted the
important roles of gut microbiota in energy harvest and metabolism in hosts 33,43,44, which
are thought to be associated with a number of diseases such as obesity, hypertension,
diabetes and cardiovascular diseases. We detected decreased amounts of citric acid or
isocitric acid in infected animals, suggesting that the citric cycle was inhibited to some
extent. The amount of FAD concurrently increased, which is consistent with reduced citric
acid cycle, as FAD is an enzyme cofactor for the conversion of succinate to fumarate, two
intermediates of the TCA cycle. A recent report noted decreased amounts of amino acids
and metabolites of the citric acid cycle in IBD tissue samples 45, which is in a good
agreement with our observation in this animal model. There is also evidence that IBD
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patients have mitochondria with reduced functions, reduced ATP generation, and reduced
production of antioxidants46.
Significantly altered energy metabolism may also account for decreased amounts of
polyunsaturated fatty acids, including linoleic acid (LA, −2.2 fold), alpha-linoleic acid
(ALA, −1.7 fold), arachidonic acid (ARA, −3.8 fold), eicosapentaenoic acid (EPA, −2.4
fold) and docosahexaenoic acid (DHA, −1.8 fold). Germ-free mice have increased fatty acid
oxidation compared to conventionally raised mice33,47, and this may generate more acetyl-
CoA, the entry molecule for the TCA cycle, which compensates reduced energy production
in malfunctioned mitochondria or increased energy uptake during inflammation. Therefore,
lower amounts of LA and ALA, as the consequence of increased oxidation, result in
decreased amounts of other downstream fatty acids such as ARA, EPA and DHA. On the
other hand, many functions of these fatty acids are mediated through their roles as acyl
moieties of membrane phospholipids and they are released to serve as substrates for further
metabolism by several important enzymes, such as cyclooxygenases etc. Thus, a greater fold
change of ARA may point to its higher involvement in eicosanoid synthesis, which is
stimulated by chronic inflammatory responses.
Aside from the contribution of gut microflora, it should be noted that inflammation-
associated hypoxia may also play a role in defining energy demand and affecting
metabolism of related pathways as discussed above48. During inflammation, a large number
of immune cells are recruited to inflammatory lesions. Cell migration, phagocytosis,
bacterial killing and stimulated cell proliferation have high energy demands 49,50.
Neutrophils, macrophages and dendritic cells primarily use glycolytic pathways to obtain
energy, while B and T cells mainly use amino acids, glucose and lipids to generate energy
during oxidative phosphorylation 48. Nutrition and oxygen can be rapidly limited or depleted
in tissues with high inflammatory lesions and elicited immune activities. Dysregulation of
gut microflora and inflammatory hypoxia may therefore have a synergistic effect on
defining the overall outcome of energy production and uptake in H. hepaticus infected
Rag2−/− mice.
Taken together, the effects of gut microbiota on blood metabolites in the Rag2 model have
been revealed by a variety of altered metabolites and metabolic pathways, including indole-
containing compounds, glycine conjugates, lipids, critic acid and fatty acids. These
observations are in good accordance with the accumulating evidence for the role of intestinal
bacteria during the progress of IBD. A number of studies have shown that the commensal
bacteria community is disturbed in IBD, which may have significant biological
consequences on the development of this disease. Here, we provide evidence for the direct
impact of gut microflora on blood metabolites in an animal IBD model. Metabolomic
analysis of human IBD serum samples are currently under investigation in our laboratory,
which could determine whether gut microflora have the same or similar effects on blood
metabolite profiles in IBD patients as it does in these mice.
We have examined both metabolomic and peptidomic profiling in our mouse model.
Peptidomics explores the peptidome that is mechanistically linked to the proteome. We have
discovered a number of elevated peptides, which could be enzymatically processed products
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generated by proteases (Figure S8), a complex family of more than 500 enzymes. Analysis
of serum peptides offers a new perspective to explore chronic inflammatory responses and to
develop potential blood biomarkers. Specifically, pathway analysis revealed several
precursor proteins, including fibrinogen, complement C4 and alpha-macroglobulin, that
were associated with acute phase and inflammatory responses (Figure S9 A). Increases of
these acute-phase proteins is a well-documented inflammatory response of the liver to
cytokines secreted by activated neutrophils, macrophages and lymphocytes51. Through
independent analysis using multiplex sample processing, we demonstrated that fibrinogen
and alpha-2-macroglobulin were also increased in serum at the protein level. In addition,
several other serum acute phase proteins were up-regulated in our animal model (Figure S9
B). These elevated serum peptides are primarily from several common proteins, such as
fibrinogen and complement C4, which is consistent with the findings by Tempst, colleagues
and others52–54. Particularly, DTEDKGEFLSEGGGV, DTEDKGEFLSEGGGV and
TDTEDKGEFLSEGGGVR all belong to the alpha chain of fibrinogen. The difference of a
single amino acid suggests a diverse enzymatic processing by proteases. The elevated
peptides in our animal model could arise from increased acute phase protein expression, or
increased protease activities in serum or both. However, the activity of exoproteases could
mask any tissue specific or disease specific protease activity. Nevertheless, Tempst, et al.,
found tumor-specific serum peptidome patterns by differential exoprotease activities53.
Likewise, our results may also suggest a different pattern of regulated serum protease
activities in infected animals. It is well documented that protease activities are up-regulated
in tissues with ongoing inflammation in IBD. For example, a previous study, using a rat IBD
model induced by dinitrobenzenesulfonic acid, has revealed 6–10-fold increased levels of
serine protease activity in colon tissue compared to control55. Elevated levels of protease
activity in tissue samples in UC patients were also reported 55. Increased protease activities
may have a key role in eliciting increased intestinal permeability, an important
physiopathology phenomenon commonly observed in IBD patients. Currently, it remains
unclear whether serum protease activities are regulated in IBD and whether these elevated
peptides are generated in vivo, or ex vivo or both. Further investigation will shed light on
this intriguing question.
In summary, we have combined metabolomics and peptidomics to analyze serum samples of
H. hepaticus infected Rag2−/−. Metabolomic profiling revealed that H. hepaticus infection
dramatically changed many global metabolite features, with the majority of metabolites
being down-regulated. We have demonstrated the involvement of gut microflora on the
blood metabolites in infected animals. The peptidomics approach identified some elevated
peptides that share sequences with proteins having diverse biological functions and
important implications for the progress of IBD. Taken together, the strategy of integrating a
relevant animal model with sensitive MS-based profiling should provide mechanistic
insights into IBD, and may suggest potential biomarkers for the diagnosis and progression of
these disorders.
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Figure 1.
The experimental workflow for the metabolite profiling performed in this study. It starts
with the metabolite extraction with methanol, followed by MS profiling under both positive
and negative ionization modes, data processing, statistical analysis, database search,
metabolite identification by tandem MS/MS and pathway analysis.
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Figure 2.
Typical LC-ESI-TOF total ion chromatograms of serum metabolites extracted from
uninfected (A) and infected animals (20 week post-infection) (B). Data were acquired under
positive ionization mode (80–1000 m/z).
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Figure 3.
Separation of uninfected and infected 20 week Rag2−/− mice by principle component
analysis (A. positive-ESI; C. negative-ESI) and the hierarchical clustering heat maps
constructed using molecular features with 1.5 fold changes (p<0.05) (B. positive-ESI; D.
negative-ESI). The ellipses represent 95% confidence interval of the uninfected (Red),
infected (Green) and all samples (Grey), respectively.
Lu et al. Page 19
J Proteome Res. Author manuscript; available in PMC 2014 May 19.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 4.
The effect of the length of H. hepaticus infection on fold changes of typical metabolites in
Rag2−/− mice relative to the uninfected groups (Fold change: + represents up-regulated
metabolites in infected animals, while – denotes down-regulated metabolites in infected
animals). Mice infected for 20 weeks have equivalent or higher fold changes for the same
metabolites compared to ten-week infected mice.
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Figure 5.
The effect of gut microflora on blood metabolites in H. hepaticus infected Rag2−/− mice.
(A.) Indole-containing metabolites (B.) Glycine conjugates (C.) The metabolism of Diadzein
to Equol.
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Figure 6.
The potential link between altered phospholipid metabolism and disturbed methionine-
homocysteine cycle in H. hepaticus infected Rag2−/− mice.
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Figure 7.
Inhibited citric acid cycle and altered fatty acid pathways in H. hepaticus infected Rag2−/−
mice. Linoleic acid: LA, alpha-linoleic acid: ALA, arachidonic acid: ARA, eicosapentaenoic
acid: EPA, docosahexaenoic acid: DHA, phospholipase A2: PLA2, flavin adenine
dinucleotide: FAD.
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Table 3
Selected identified peptides that significantly elevated in H. hepaticus infected Rag2−/− mice 20 week post-
infection and their corresponding protein sources.
Peptide sequence Score Fold Protein
(T)TDTEDKGEFLSEGGGV(R) 98 +3.3 Fibrinogen, alpha polypeptide isoform 2
(T)TDTEDKGEFLSEGGGVR(G) 89 +2.1 Fibrinogen, alpha polypeptide isoform 2
(T)DTEDKGEFLSEGGGV(R) 80 +2.6 Fibrinogen, alpha polypeptide isoform 2
(A)ADDDYDEPTDSLDA(R) 96 +2.7 Fibrinogen, beta chain precursor
(A)DDPSVPLQPVTPLQLFEGRRS(R) 78 +4.3 Complement C4
(K)ALSFYQPRAPSAEVEMTAYVLLAYLTSESSRPT(R) 84 +2.1 Alpha-2-macroglobulin
(V)PQINDALGADESLLNRLYGFLQSGDSLNPLLASF(F) 73 +2.1 Serine/threonine-protein phosphatase 6 regulatory subunit 1
(Q)QPPQPEGEEDASDGGRKRGQAGWEGGYPE(I) 68 +2.4 Myc-induced SUN domain containing protein
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